0 CHECKOUT

PRODUCT FILTERS

REGION

1,215
582
579
524
524

COUNTRY

510
126
54
52
51

CATEGORIES

  • 314
  • 245
  • 234
  • 234
  • 211
  • 170
  • 161
  • 161
  • 140
  • 137
  • 135
  • 127
  • 80
  • 74
  • 42

PRICE

351
813
1,485
3,448

PUBLISHED

249
834
1,609
3,448

PRODUCT TYPE

2,630
358
293
136
26
2
1
1
1

Oncology Drugs

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

Sphingosine 1-Phosphate (S1P) Inhibitors -Pipeline Insights, 2016

SUMMARY The report, “Sphingosine 1-Phosphate (S1P) Inhibitors-Pipeline Insights, 2016” provides in depth insights on the pipeline drugs and their development activities around the Sphingosine 1-Phosphate...

Published:  March 2016
Price:  From

Heat Shock Protein 70 (Hsp70) Inhibitors -Pipeline Insights, 2016

SUMMARY The report, “Heat Shock Protein 70 (Hsp70) Inhibitors-Pipeline Insights, 2016” provides in depth insights on the pipeline drugs and their development activities around the Heat Shock Protein...

Published:  March 2016
Price:  From

Heat Shock Protein 27 (Hsp27) Inhibitors -Pipeline Insights, 2016

SUMMARY The report, “Heat Shock Protein 27 (Hsp27) Inhibitors-Pipeline Insights, 2016” provides in depth insights on the pipeline drugs and their development activities around the Heat Shock Protein...

Published:  March 2016
Price:  From

Heat Shock Protein (Hsp) Inhibitors -Pipeline Insights, 2016

SUMMARY The report, “Heat Shock Protein (Hsp) Inhibitors-Pipeline Insights, 2016” provides in depth insights on the pipeline drugs and their development activities around the Heat Shock Protein (Hsp)...

Published:  March 2016
Price:  From

Janus Kinase 3 (JAK3) Inhibitors -Pipeline Insights, 2016

SUMMARY The report, “Janus Kinase 3 (JAK3) Inhibitors-Pipeline Insights, 2016” provides in depth insights on the pipeline drugs and their development activities around the Janus Kinase 3 (JAK3) Inhibitors....

Published:  March 2016
Price:  From

Janus Kinase 1 (JAK1) Inhibitors -Pipeline Insights, 2016

SUMMARY The report, “Janus Kinase 1 (JAK1) Inhibitors-Pipeline Insights, 2016” provides in depth insights on the pipeline drugs and their development activities around the Janus Kinase 1 (JAK1) Inhibitors....

Published:  March 2016
Price:  From

Janus Kinase (JNK) Pathway Inhibitors -Pipeline Insights, 2016

SUMMARY The report, “Janus Kinase (JNK) Pathway Inhibitors-Pipeline Insights, 2016” provides in depth insights on the pipeline drugs and their development activities around the Janus Kinase (JNK)...

Published:  March 2016
Price:  From

Janus Kinase (JAK) Inhibitors -Pipeline Insights, 2016

SUMMARY The report, “Janus Kinase (JAK) Inhibitors-Pipeline Insights, 2016” provides in depth insights on the pipeline drugs and their development activities around the Janus Kinase (JAK) Inhibitors....

Published:  March 2016
Price:  From

Anaplastic Lymphoma Kinase (ALK) Inhibitors -Pipeline Insights, 2016

SUMMARY The report, “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights, 2016” provides in depth insights on the pipeline drugs and their development activities around the Anaplastic Lymphoma...

Published:  March 2016
Price:  From

PI3K/AKT/mTOR Pathway Inhibitors -Pipeline Insights, 2016

SUMMARY The report, “PI3K/AKT/mTOR Pathway Inhibitors-Pipeline Insights, 2016” provides in depth insights on the pipeline drugs and their development activities around the PI3K/AKT/mTOR Pathway Inhibitors....

Published:  March 2016
Price:  From

Apoptosis Inhibitors -Pipeline Insights, 2016

SUMMARY The report, “Apoptosis Inhibitors-Pipeline Insights, 2016” provides in depth insights on the pipeline drugs and their development activities around the Apoptosis Inhibitors. The report covers...

Published:  March 2016
Price:  From

C-Raf Kinase Inhibitors -Pipeline Insights, 2016

SUMMARY The report, “C-Raf Kinase Inhibitors-Pipeline Insights, 2016” provides in depth insights on the pipeline drugs and their development activities around the C-Raf Kinase Inhibitors. The report...

Published:  March 2016
Price:  From

Inhibitors of Apoptosis (IAP) Antagonists -Pipeline Insights, 2016

SUMMARY The report, “Inhibitors of Apoptosis (IAP) Antagonists-Pipeline Insights, 2016” provides in depth insights on the pipeline drugs and their development activities around the Inhibitors of Apoptosis...

Published:  March 2016
Price:  From

Somatostatin Receptor Agonist -Pipeline Insights, 2016

SUMMARY The report, “Somatostatin Receptor Agonist-Pipeline Insights, 2016” provides in depth insights on the pipeline drugs and their development activities around the Somatostatin Receptor Agonist....

Published:  March 2016
Price:  From

Recurrent Glioblastoma Multiforme (GBM)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

SUMMARY The Report, “Recurrent Glioblastoma Multiforme (GBM)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug...

Published:  March 2016
Price:  From

Glioblastoma Multiforme (GBM)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

SUMMARY The Report, “Glioblastoma Multiforme (GBM)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase...

Published:  March 2016
Price:  From

Small-Cell Lung Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

SUMMARY The Report, “Small-Cell Lung Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III...

Published:  March 2016
Price:  From

Testicular Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

SUMMARY The Report, “Testicular Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline...

Published:  March 2016
Price:  From

T-Cell Leukemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

SUMMARY The Report, “T-Cell Leukemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline...

Published:  March 2016
Price:  From

Relapsed Multiple Myeloma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

SUMMARY The Report, “Relapsed Multiple Myeloma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III...

Published:  March 2016
Price:  From
Loading Indicator

Our Clients